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Measuring and interpretation of the immune response to
pneumococcal polysaccharides is a complex field, owing to the
diversity of the pneumococcal polysaccharide capsular types,
different vaccine formulations including both polysaccharide
and conjugate vaccines, diverse pneumococcal serological
assays, lack of immunogenicity data for the conjugate in a
number of at-risk groups and complex vaccine schedules. Even
the reasons for performing pneumococcal serology can be
complex, as assays may be performed for one of two reasons:
either to assess an individual’s immune status to the
pneumococcus or to discriminate between normal and
abnormal humoral immunity. This review details a history of the
pneumococcal serological assays and provides some insight
into when serology can prove useful, including vaccination data
for certain at-risk groups.
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I
nfections caused by pneumococci are a major
cause of morbidity and mortality worldwide.
Pneumonia, febrile bacteraemia and meningitis
are the most common manifestations of invasive
pneumococcal disease (IPD), whereas bacterial
spread within the respiratory tract may result in
middle-ear infection, sinusitis or recurrent bron-
chitis. Compared with invasive disease, the non-
invasive manifestations are usually less severe, but
considerably more common. Although all age
groups may be affected, the highest rate of
pneumococcal disease occurs in young children
when immune responsiveness to sugar-protein
moieties on the surface of pneumococci is poorly
developed, and in the elderly population when it
has waned. In addition, individuals suffering from
a wide range of chronic conditions and immune
deficiencies are at increased risk, in particular
partial or complete antibody deficiency, comple-
ment defects, and congenital or acquired asplenia.
The capsular polysaccharides of Streptococcus pneu-
moniae represent a diverse group of polymers that
play an essential role in the virulence of the
bacterium, with 90 serologically distinct capsules
now recognised.1
The polyvalent polysaccharide vaccine
(Pneumovax) contains 25 mg of the capsular
polysaccharides of 23 serotypes (1, 2, 3, 4, 5, 6B,
7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C,
19F, 19A, 20, 22F, 23F and 33F; 23vPPV) that are
currently responsible for the vast majority of
invasive pneumococcal infection. However, the
usefulness of this vaccine is limited owing to the
T-cell-independent nature of the immune response
to polysaccharide antigens and its consequent
failure to induce long-term protection and lack of
efficacy in children ,2 years of age. As a result, it
is licensed for use only in individuals aged
.2 years.2
A 7-valent pneumococcal saccharide–protein con-
jugate vaccine (7vPCV; Prevenar) has recently been
licensed, which has been shown to be highly
immunogenic in young children with an estimated
efficacy of 97.3% against vaccine serotypes following
three doses.3 The 7vPCV contains approximately
2 mg of saccharide from serotypes 4, 9V, 14, 18C, 19F
and 23F and 4 mg from serotype 6B. The seven
serotypes included in Prevenar are among the most
prevalent of those causing IPD in the targeted age
group (,5 years of age), and, although universal
immunisation of infants has been recommended in
the US4 for some time, the UK, since 2001, has
recommended 7vPCV only for children ,2 years of
age in high-risk groups.2 In July 2006, the UK
Department of Health (DH) announced the intro-
duction of the 7vPCV to the routine infant immu-
nisation schedule, with three doses to be given at 2,
4 and 13 months from 4 September 2006.5 A catch-
up campaign for those aged up to 2 years of age will
also be implemented. For persons aged>65 years, a
single dose of 23vPPV is recommended and patient
groups at risk of IPD are recommended to be
immunised according to the guidelines recom-
mended by the DH.6 The at-risk groups include
those with anatomical or functional asplenia;
chronic renal disease or nephrotic syndrome;
immunodeficiency or immunosuppression due to
disease or treatment (including HIV infection);
chronic heart, lung and liver disease; and diabetes
mellitus. Previous IPD irrespective of serotype is not
considered a risk factor, and hence pneumococcal
immunisation is not generally recommended. An
enhanced surveillance programme has been put in
Abbreviations: CP, C-polysaccharide; HAART, highly
active antiretroviral therapy; IPD, invasive pneumococcal
disease; RIA, radioimmunoassay; PPV, pneumococcal
polysaccharide vaccine; 7vPCV, 7-valent pneumococcal
conjugate vaccine; 23vPPV, 23-valent pneumococcal
polysaccharide vaccine
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place, which will monitor the impact of the 7vPCV on IPD and
follow up potential vaccine failures.7 For children in birth cohorts
targeted for routine or catch-up immunisation with confirmed
IPD, vaccinated is dependent on their prior vaccine history and
infecting serotype. If unvaccinated or partially vaccinated, a
primary/booster schedule of 7vPCV should be offered. If fully
vaccinated and a true vaccine failure, a further dose is offered,
whereas for non-vaccine serotype cases or those where the
serotype is not known, the decision to re-vaccinate is based on the
pneumococcal serotype-specific serology.8
Both 23vPPV and 7vPCV are considered safe vaccines based
on clinical experience since 1977 and 2000, respectively. Local
reactions at the site of injection, such as mild soreness, swelling
and redness, are observed following administration of both
vaccines, along with low-grade fever. More severe systemic
reactions are infrequent.4 6 8
SEROLOGICAL ASSAYS
Pneumococcal serological assays are performed for two main
reasons. Firstly, an individual’s immune status to the pneumo-
coccus is assessed by seeing whether seroconversion occurs
following vaccination, and so determining whether he/she is
protected or requires vaccinated, and, if so, whether with
23vPPV or with 7vPCV (eg, for asplenia and chronic renal
disease). Secondly, serology is performed to discriminate
between normal and abnormal humoral immunity by using
the 23vPPV as a T-cell-independent polysaccharide antigen (eg,
for hypoglobulinaemia or a-c-globulinaemia, Wiskott–Aldrich
syndrome or DiGeorge anomaly). Depending on which question
is being asked, different serological assays may be used.
Up to the 1980s, the radioimmunoassay (RIA) and indirect
haemagglutination assay were utilised to measure antibody
responses following pneumococcal vaccination. The indirect
hemagglutination assay was reproducible but not as quantita-
tive as the RIA.9 10 Although sensitive and reproducible, the RIA
has several disadvantages—namely expense, inability to differ-
entiate immunoglobulin isotypes, and safety issues with the use
of radiolabelled polysaccharides.
Over the past 30 years, a number of ELISA methodologies for
the measurement of antibodies against pneumococcal poly-
saccharides have been developed. Broadly, these fall into two
categories depending on whether the assay was for clinical
management or for vaccine trial. Until the licensure of the
Prevenar in 2000 in the US,4 only polysaccharide vaccine was
available and the clinical ELISA methodologies used actual
23vPPV as antigen.11 12 For vaccine trials, serotype-specific IgG
assays were developed and utilised.13 14 For these assays, a
consensus methodology,15 as well as internationally available
standards are available. These ELISAs have now been trans-
ferred to the Luminex platform to give a rapid, multianalyte
particle-based flow cytometric assay.16 17 Pneumococcal IgG
ELISA can suffer from poor specificity, as the test antigen, both
23vPPV and purified specific polysaccharide, contains both
serotype-specific polysaccharides and C-polysaccharide (CP).
Antibodies to the CPs are not protective,18 and so measurement
of non-functional IgG antibody to CP may give misleading
results, suggesting that a patient has protective antibody-
mediated immunity when in fact he or she does not have it.19
Interestingly, the RIA was less affected than the ELISA by anti-
CP antibody.20
Before the licensure of 7vPCV, when only 23vPPV was
available, it was not deemed necessary to measure individual
serotype-specific IgG concentrations for clinical management.
This would have been laborious to perform and, assuming that
the ELISA utilised had been absorbent to remove non-
functional antibodies, gave a good indication of whether a
patient had responded to vaccination and whether he or she
had normal or abnormal humoral immunity.21 However, when
patients have been immunised with pneumococcal conjugate
vaccine, use of vaccine, whether 23vPPV or 7vPCV, as the assay
antigen is not so appropriate. One small study compared an
ELISA using pneumococcal polysaccharide vaccine (PPV) as
antigen with a serotype-specific IgG assay, and demonstrated
that only the latter could discriminate responders.22 The lack of
specificity of the 23-valent assay may be because of the
suboptimal expression of the 7 serotype polysaccharides in
question on the ELISA plate. The added benefit of the serotype-
specific IgG ELISA was also demonstrated by Uddin et al.23
Children with a history of recurrent or severe bacterial
infections received two doses of 7vPCV followed by a single
dose of 23vPPV; their specific IgG against two of the serotypes
not covered by the 7vPCV but only by the 23vPPV remained
low. The 23-valent assay was, however, of use as a simple
screen for the distinction between normal and abnormal
immunity.
The use of 23vPPV as an example of a T-independent
polysaccharide antigen for the investigation of individuals with
abnormal immunity became problematic following the DH
recommendation for use of 7vPCV in at-risk groups,24 and will
become virtually inoperative following the introduction of
7vPCV into the infant immunisation schedule in 2006–7.5 If
subjects are already primed by a pneumococcal polysaccharide–
protein conjugate vaccine, later administration of a polysac-
charide should elicit an anamnestic-type response. Thus, the
polysaccharide will not behave as a classical T-independent
antigen. This could be overcome by the immunological
investigation of pneumococcal serotypes that are not contained
within the 7vPCV but are in the 23vPPV, such as serotypes 1
and 5. Caution should be exercised if a serotype is selected that
is represented in the 7vPCV by another serotype such as 6A or
6B, because antibodies to one have been shown to cross-react
with the other,25 26 or even other bacterial capsules such as
pneumococcal serotype 6B with Haemophilus influenzae type b.27
An alternative approach would be to use a different poly-
saccharide vaccine altogether. Polysaccharide vaccines from
meningococcal serogroup C and H influenzae type b are not
suitable, as conjugate vaccines containing antigens from these
pathogens are widely utilised. Other serogroups of the non-
conjugated meningococcal quadrivalent polysaccharide vaccine
could be utilised as, to date, Menactra, the only licensed
quadrivalent meningococcal A, C, Y and W135 conjugate
vaccine, is licensed only in the US.28 Of the meningococcal
serogroups, Y and W135 capsular polysaccharides may be
suitable, although the appropriateness of serogroup A is in
question, as this serogroup polysaccharide is not a classical T-
independent antigen.29 Alternatively, Salmonella typhi Vi capsu-
lar polysaccharide vaccine could be utilised and immunoassays
have been developed for quantitation of antibody to this
antigen.30 However, it must be remembered that S typhi
conjugate vaccines are under development.31
PROTECTIVE LEVELS AND NORMAL RANGES
Defining protective antibody levels and even normal ranges for
pneumococcal IgG antibody is problematic, as the protective
level may be different for different serotypes and may also vary
with age. Numerous attempts have been made to assign normal
ranges11 and protective levels,3 and define tools for the
interpretation for clinical management.19
In infants receiving the 7-valent conjugate vaccine at 2, 4 and
6 months, >97% achieved >0.15 mg/ml of anticapsular anti-
bodies for all serotypes within the vaccine.3 This correlated with
the observed protective efficacy of 97.3%. From this, a serotype
non-specific threshold concentration of 0.20 mg/ml was
obtained with the support of additional factors.32 Firstly, an
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antibody concentration >0.20 mg/ml corresponds to the thresh-
old of opsonic antibody titre of 1:8. Secondly, the threshold
concentration also seems to predict the age-specific population
disease rates, with the rates increasing when passively acquired
antibody concentrations fall below 0.20 mg/ml, but decreasing
when naturally acquired antibody concentrations rise above
this concentration. Thirdly, the threshold is consistent with
available data from passive immunisation studies on the level
of bacterial polysaccharide immune globulin needed to prevent
pneumococcal otitis media33 and IPD.34 This threshold seems to
clearly discriminate between conjugate vaccines and controls in
immunogenicity studies.32 Recently, the World Health
Organization has proposed a threshold of 0.35 mg/ml for use
with the serotype-specific assay with CPs but not with 22F as
adsorbent.35 This has been reported to correlate with a thresh-
old of 0.20 mg/ml when using both CPs and 22F as adsorbents,
although this is still under debate for sera from infants.36 37
Scientifically, a threshold derived from vaccine efficacy in a
population(s) cannot be used to precisely discriminate indivi-
dual people at risk from those who are not. There are numerous
examples of individual-breakthrough cases occurring despite
protective pre-existing antibody concentrations, for a number
of different pathogens,38 although in some cases disease may be
attenuated. It is likely that differences in exposure, microbial
virulence and various host factors including innate immunity
and concurrent viral infections make an individual’s risk
difficult to predict precisely.
An algorithm has been designed to attempt to generate
manageable data in the form of an overall susceptibility of
infection to the pneumococcal serotypes included in the
serotype-specific assay. The prevalence of each of the serotypes
in defined age groups was combined with the then-putative
protective level of 0.15 mg/ml to generate a percentage suscept-
ibility to infection.19 A threshold of >10% overall susceptibility
on the serotype-specific assay is taken to indicate the need for
intervention such as vaccination if appropriate.19
It is not possible to assign protective thresholds for the assays
that utilise 23vPPV as antigen, as these assays have never been
utilised in efficacy studies or contrasted to the functional
opsonic assays. However, a number of papers do describe
normal ranges or ranges that may discriminate between normal
and abnormal immunity.11 23 39 Given that little effort has been
made with regard to the interlaboratory standardisation of
these 23vPPV assays, there are no national or international
calibrant materials available, and, as they are normally
endpoint titre assays, a normal range from one laboratory
could not be translated to that of another.
IMMUNOGENICITY OF 7VPCV AND 23VPCV IN AT-
RISK GROUPS
Given the relatively recent licensure of 7vPCV, there are still few
data on its immunogenicity in different risk groups and also on
the effect of polysaccharide vaccination either before or after
7vPCV vaccination. Serological analysis following 7vPCV is
therefore advisable in these groups.
In the UK, it is currently recommended that ‘‘at-risk’’
children ,5 years of age are given a single dose of 23vPPV
after the second birthday following on from the recommended
primary course of 7vPCV for their age group.6 Although this
approach is well tolerated, few studies have been performed
with the current serotype-specific assays to determine the
added potential advantage of using 23vPPV to broaden cover-
age. One concern is that there is some evidence from studies
with meningococcal vaccines that administration of polysac-
charide vaccine following immunisation with conjugate vaccine
may interfere with the memory B cell pool.40 This may be of
particular interest in the northern territory of Australia, where
7vPCV is administered in a primary series at 2, 4 and 6 months
of age, with only indigenous children receiving a 23vPPV
booster at 18 months.41
Studies of response to meningococcal vaccines suggest that
administration of polysaccharide vaccines may reduce the
magnitude and persistence of antibody responses to subsequent
conjugate vaccines.42 Both of these need to be studied for
pneumococcal vaccines, now that there are immunoassays
capable of discerning what interactions are occurring. The latter
is of particular importance in that 23vPPV is utilised as a
polysaccharide probe to ascertain whether a patient is able to
respond generically to polysaccharides or not. Serological data
are available which demonstrate that an initial dose of 23vPPV
in subjects aged >70 years leads to a decreased antibody
response to subsequent 7vPCV.43 No published data are
available for children.
Although hyporesponsiveness has been clearly demonstrated
after repeated doses of meningococcal group C polysaccharide
vaccine,44–46 this question is more complex following repeated
doses of 23vPPV. In the 1970s, in a study of a 12-valent PPV
given either as two doses in infancy at 3–5 months and at 9–
11 months or as a single dose at 6–12 months of age, antibody
levels of 9 of the 10 serotypes assayed for were lower at
1 month following two doses as opposed to a single dose.47 In a
study of patients undergoing treatment for community-
acquired pneumonia who were vaccinated with 23vPPV and
re-vaccinated 4–7 years later, vaccinated resulted in significant
increases in antibody concentration, although to lower levels
than after primary vaccination for all six serotypes assayed for
(1, 4, 7F, 14, 18C and 19F).48 Recent data from the US
demonstrate that a second dose of 23vPPV is immunogenic in
older adults and that the antibody levels remain increased
relative to baseline for 5 years after vaccination.49 Interestingly,
for the four serotypes studied, serotype-specific IgG geometric
mean concentrations were either similar (serotypes 3 and 23F)
or lower (serotypes 4 and 14) in the vaccinated groups. Few
data following repeated vaccination with 23vPPV in children
are available. In a study in toddlers of multiple regimens of an
investigational pneumococcal conjugate and 23vPPV, a non-
randomised comparison of a single dose of 23vPPV as compared
with two doses of 23vPPV, given 12 months apart, was
possible.50 Following two doses of 23vPPV, antibody levels to
serotype 14 were higher than following a single dose, but lower
for 23F. For the other five serotypes assayed, antibody levels
against serotype 19F were potentially higher following two
doses as opposed to one, potentially lower for serotypes 4, 6B
and 9V and similar for serotype 18C. Therefore, hyporespon-
siveness following repeated doses of 23vPPV has been demon-
strated for certain serotypes but there is little agreement
between studies. More importantly, the clinical relevance of
this is not known.
For the clinician, 7vPCV is an obvious choice in infection-
prone subjects who are non-responders to the 23vPPV. Studies
have demonstrated that the 7vPCV is more immunogenic than
the 23vPPV in this group, although children did show a
significantly lower post-vaccination antibody levels than
healthy controls previously naive to pneumococcal
vaccination.51 It is an interesting question whether these
children would have responded in a manner more similar to the
controls if they had not received 23vPPV earlier. A different
study in adults again demonstrated the immunogenicity of
7vPCV in adults with specific antibody deficiency; however, two
doses were required to mount a suitable response.52
Invasive pneumococcal infection is still a prevalent disease
among the HIV-infected population in certain countries, even
in the era of highly active antiretroviral therapy (HAART).53
Several studies have assessed the antibody response of
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HIV-infected individuals to 23vPPV; in the pre-HAART era,
most studies showed an impaired response compared with
healthy controls.54–57 By comparison, HIV infected individuals
receiving HAART responded to 23vPPV at least as well as
healthy individuals.58 Immunisation of HIV-1-positive infants
(n = 30) with three doses of 7vPCV was found to be
immunogenic, with 88–100% achieving a fourfold rise in
serotype-specific IgG levels depending on serotype; 95% had a
level >0.15 mg/ml.59 At 15 months of age, antibody levels to the
seven serotypes were still above baseline levels and approxi-
mately 70% had a fourfold rise following administration of a
booster, except for serotype 14, to which only 39% had a
fourfold rise, but this was probably owing to the higher pre-
booster levels than the other serotypes. A study in 14 Greek
symptomatic HIV-1 children (median age 128 months), how-
ever, demonstrated lower serotype-specific geometric mean
antibody concentrations following two doses of 7vPCV as
compared with the 21 age-matched controls, and predicted that
long-term effectiveness was expected to be reduced among
infected children.60
Few data are currently available on antibody responses
following 7vPCV dose in patients with haematological diseases.
Patients undergoing haematopoietic cell transplantation are at
increased risk for infections with S pneumoniae61 and have long-
lasting, impaired antibody responses to PPVs.62 Molrine et al63
randomised non-T-cell-depleted sibling allogenic recipients for
pre-transplantation immunisation with 7vPCV. This was for
both the donor and for the recipient with vaccination 7–10 days
pretransplant. All patients then received 7vPCV at 3, 6 and
12 months. Significantly higher antibody levels were detected
at all time points up to 12 months for the group which had
received pretransplantation vaccination. After 12 months, with
the exception of serotype 6B, the antibody levels were similar. A
further study64 explored the use of pretransplant immunisation
with 7vPCV in patients undergoing autologous transplantation.
Vaccination with 7vPCV was given at a mean of 10 days before
autologous stem cell collection in those randomised to receive
precollection vaccination. Vaccination was again at 3, 6 and
12 months and, up to 12 months, the antibody levels were
significantly higher in those who had received 7vPCV before
transplantation. On the basis of these two studies, three doses
of 7vPCV starting 6–12 months after transplantation are now
recommended by the European Group for Blood and Marrow
Transplantation for small children and patients undergoing
stem cell transplantation.65
The loss of splenic function is associated with an increased
risk of life-threatening pneumococcal infection. Immunological
responses to 23vPPV in asplenics vary; healthy patients who
have undergone splenectomy owing to trauma gave responses
similar to those of controls, whereas patients with an under-
lying immunological disease as well as healthy asplenic patients
did not respond.66 Few data exist in asplenics following 7vPCV
vaccination. One small study in children demonstrated that
protective antibody levels induced by 7vPCV varied according to
serotype, ranging from 100% response for serotypes 18C and
19F to 40% for serotype 6B.67 Another report detailed two
patients who had recurring pneumococcal bacteraemia after
undergoing splenectomy despite having received numerous
doses of 23vPPV. Following the administration of 7vPCV, high
levels of serotype-specific IgG were induced to the seven
serotypes.68 A study in 39 near or totally splenectomised
patients with hereditary spherocytosis, aged 5–27 years,
demonstrated that receiving a single dose of 7vPCV showed
significant rises in the serotypes contained within 7vPCV.69
Children with nephrotic syndrome, renal allografts or chronic
renal insufficiency have an increased risk of pneumococcal
disease owing to urinary loss of immunoglobulin, immune
suppression from their disease and/or drug therapy. A review of
26 published studies of 23vPPV in this population demon-
strated serological responses by the majority of patients to at
least some pneumococcal serotypes, and the use of steroids did
not alter this response. In the studies with .6-month follow-
up, declining antibody titres were consistently reported, and
this decline was usually more rapid than in healthy controls.70
Very few data are available on responses to 7vPCV in this
patient group. A small study has shown that, in children
.5 years of age, 7VPCV was immunogenic and that immune
suppression did not influence the antibody response.71
However, there is a report from the US of vaccine failure in a
7-year-old due to serotype 23F 2 months after a single dose of
7vPCV.72 The population-based surveillance in which this was
highlighted also cited vaccine failure with comorbid conditions
including chronic lung disease, leukaemia, heart disease and
HIV, and also described non-traditional comorbidity features
that were associated with cases of IPD such as asthma, eczema,
seizure disorder, central nervous system disease, prematurity,
lupus and metabolic disorder.72
THE FUTURE
With the recommendation of the use of Prevenar in at-risk
groups aged ,5 years in 200424 and its imminent introduction
into the UK infant immunisation schedule,7 it is anticipated
that the need for pneumococcal antibody testing will increase,
in particular during the enhanced surveillance period following
the introduction of Prevenar. Also, until more experience is
gained with the use of 7vPCV in various at-risk cohorts,
serological monitoring of patients is advised to obtain further
knowledge of the immunogenicity of the pneumococcal
conjugates.
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Take-home messages
N Measurement of pneumococcal-specific antibodies pro-
vides the assessment of immunity to the pneumococcus or
investigation of a potential immunodeficiency.
N Interpretation of the data should always be related to the
clinical history that prompted the request for testing.
N The introduction of the seven-valent pneumococcal
conjugate vaccine into the infant immunisation schedule
and the increased use of this vaccine in at-risk patient
groups will result in more pneumococcal serology being
performed.
N For assessment of response to the conjugate vaccine, the
assay used needs to be serotype-specific.
N Measurement of anti-pneumococcal antibodies will also
increase the knowledge of the immunogenicity of the
conjugate vaccine in at-risk patient groups, for which at
the moment there is limited data available.
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